This biopharma’s drug could be a home run for investors.
News & Analysis: Aurinia Pharmaceuticals
Here's how one biotech company can make investors rich, and why another should be avoided.
These drug developers will give your portfolio a boost.
AUPH earnings call for the period ending March 31, 2020.
Could both of these volatile stocks be winners in the long run?
These three developmental-stage pharma stocks are attracting some of the smartest investors right now.
These developers of drugs for cancer, neurological conditions, and rare diseases may boost risk-taking investors' portfolios.
These two biotechs have major drugs that should be hitting the market soon.
Aurinia’s close-to-market products make the company a good investment whether it gets a buyout offer or not.
Amarin and Aurinia will probably be bought out before the end of 2020. Here's why.